Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.8% year on year to $697 million. The company’s full-year revenue guidance of $2.5 billion at the midpoint came in 8.7% below analysts’ estimates. Its non-GAAP profit of $0.18 per share was 50.7% below analysts’ consensus estimates.
Is now the time to buy Fortrea? Find out in our full research report.
Revenue: $697 million vs analyst estimates of $703.2 million (1.8% year-on-year decline, 0.9% miss)
Adjusted EPS: $0.18 vs analyst expectations of $0.37 (50.7% miss)
Adjusted EBITDA: $56 million vs analyst estimates of $75.16 million (8% margin, 25.5% miss)
Management’s revenue guidance for the upcoming financial year 2025 is $2.5 billion at the midpoint, missing analyst estimates by 8.7% and implying -7.3% growth (vs -5.1% in FY2024)
EBITDA guidance for the upcoming financial year 2025 is $185 million at the midpoint, below analyst estimates of $277.6 million
Operating Margin: -8%, down from -3.4% in the same quarter last year
Free Cash Flow Margin: 2.9%, up from 1.3% in the same quarter last year
Market Capitalization: $1.24 billion
“Our intense focus on our customers’ success and creating a better customer experience has resulted in the stronger demand that is reflected in this quarter’s book-to-bill,” said Tom Pike, chairman and CEO of Fortrea.
Spun off from Labcorp in 2023, Fortrea Holdings (NASDAQ:FTRE) provides contract research and development services for pharmaceutical and biotechnology companies, specializing in clinical trials, laboratory services, and data management.
Companies specializing in drug development inputs and services play a crucial role in the pharmaceutical and biotechnology value chain. Essential support for drug discovery, preclinical testing, and manufacturing means stable demand, as pharmaceutical companies often outsource non-core functions with medium to long-term contracts. However, the business model faces high capital requirements, customer concentration, and vulnerability to shifts in biopharma R&D budgets or regulatory frameworks. Looking ahead, the industry will likely enjoy tailwinds such as increasing investment in biologics, cell and gene therapies, and advancements in precision medicine, which drive demand for sophisticated tools and services. There is a growing trend of outsourcing in drug development for nimbleness and cost efficiency, which benefits the industry. On the flip side, potential headwinds include pricing pressures as efforts to contain healthcare costs are always top of mind. An evolving regulatory backdrop could also slow innovation or client activity.
Story Continues
A company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Fortrea struggled to consistently generate demand over the last three years as its sales dropped at a 4.1% annual rate. This was below our standards and suggests it’s a low quality business.
Fortrea Quarterly Revenue
Long-term growth is the most important, but within healthcare, a stretched historical view may miss new innovations or demand cycles. Fortrea’s recent history shows its demand has stayed suppressed as its revenue has declined by 6.7% annually over the last two years.
Fortrea Year-On-Year Revenue Growth
This quarter, Fortrea missed Wall Street’s estimates and reported a rather uninspiring 1.8% year-on-year revenue decline, generating $697 million of revenue.
Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months. Although this projection suggests its newer products and services will spur better top-line performance, it is still below average for the sector.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Fortrea was profitable over the last four years but held back by its large cost base. Its average operating margin of 1.9% was weak for a healthcare business.
Analyzing the trend in its profitability, Fortrea’s operating margin decreased by 9.7 percentage points over the last four years. This performance was caused by more recent speed bumps as the company’s margin fell by 13.6 percentage points on a two-year basis. We’re disappointed in these results because it shows its expenses were rising and it couldn’t pass those costs onto its customers.
Fortrea Trailing 12-Month Operating Margin (GAAP)
This quarter, Fortrea generated an operating profit margin of negative 8%, down 4.6 percentage points year on year. This contraction shows it was recently less efficient because its expenses increased relative to its revenue.
We track the change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Sadly for Fortrea, its EPS declined by more than its revenue over the last three years, dropping 49.8% annually. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.
Fortrea Trailing 12-Month EPS (Non-GAAP)
In Q4, Fortrea reported EPS at $0.18, up from $0.04 in the same quarter last year. Despite growing year on year, this print missed analysts’ estimates. Over the next 12 months, Wall Street expects Fortrea’s full-year EPS of $0.33 to grow 297%.
We struggled to find many positives in these results. Its full-year revenue guidance missed significantly and its full-year EBITDA guidance fell short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock traded down 6.2% to $13 immediately following the results.
Fortrea’s earnings report left more to be desired. Let’s look forward to see if this quarter has created an opportunity to buy the stock. The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.
